Sushil Patel - 29 Jun 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Director
Issuer ticker: RVMD
Reported as of: 29 Jun 2026
Net transaction value: -$1,048,967
SEC form: 4
Accepted by SEC: 01 Jul 2026, 18:25:05 UTC
Prior SEC filing: 23 Jun 2026
Next SEC filing: 12 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Sushil Patel

Key filing fact

Sushil Patel filed Form 4 for Revolution Medicines, Inc. (RVMD) on 01 Jul 2026.

Key facts

This page summarizes Sushil Patel's Form 4 filing for Revolution Medicines, Inc. (RVMD).
11 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Jul 2026, 18:25.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: -$1,048,967.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001860609 Primary reporting owner

Patel Sushil

Relationship: Director
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DR, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Sushil Patel
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,955
Change %: +12%
Price: $37.54^*
Shares after: 27,236
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: $54,952
Shares: -300
Change %: -1.1%
Price: $183.17
Shares after: 26,936
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

RVMD transaction

Common Stock

Sale

Transaction value: $166,128
Shares: -900
Change %: -3.3%
Price: $184.59
Shares after: 26,036
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F4

RVMD transaction

Common Stock

Sale

Transaction value: $204,489
Shares: -1,100
Change %: -4.2%
Price: $185.90
Shares after: 24,936
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F5

RVMD transaction

Common Stock

Sale

Transaction value: $160,374
Shares: -858
Change %: -3.4%
Price: $186.92
Shares after: 24,078
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F6

RVMD transaction

Common Stock

Sale

Transaction value: $56,348
Shares: -300
Change %: -1.2%
Price: $187.83
Shares after: 23,778
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F7

RVMD transaction

Common Stock

Sale

Transaction value: $18,857
Shares: -100
Change %: -0.42%
Price: $188.57
Shares after: 23,678
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: $114,327
Shares: -600
Change %: -2.5%
Price: $190.54
Shares after: 23,078
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F8

RVMD transaction

Common Stock

Sale

Transaction value: $103,800
Shares: -541
Change %: -2.3%
Price: $191.87
Shares after: 22,537
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F9

RVMD transaction

Common Stock

Sale

Transaction value: $169,693
Shares: -881
Change %: -3.9%
Price: $192.61
Shares after: 21,656
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F10

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -2,955
Change %: -19%
Price: $0.000000^*
Shares after: 13,000
Date: 29 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,955
Exercise price: $37.54
Footnotes: F1, F11

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 11 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026.

Footnote F2

Includes 1,191 restricted stock units.

Footnote F3

The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F4

The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F5

The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F6

The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F7

The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F8

The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F9

The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F10

The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F11

Fully vested.